|
시장보고서
상품코드
2078334
화학요법 유발 빈혈 시장 규모, 점유율 및 성장 분석 : 치료법별, 암 유형별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Chemotherapy Induced Anemia Market Size, Share, and Growth Analysis, By Treatment (Erythropoiesis-Stimulating Agents, Blood Transfusion), By Cancer Type, By Distribution, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 화학요법 유발 빈혈 시장 규모는 2024년에 15억 2,000만 달러로 평가되었고, 2025년 16억 1,000만 달러에서 2033년까지 25억 2,000만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 5.81%를 기록할 전망입니다.
세계 화학요법 유발 빈혈 시장은 적혈구 조혈 자극 인자, 철분제, 바이오시밀러 등 화학요법에 따른 빈혈의 예방, 진단, 치료를 목적으로 하는 다양한 제품 및 서비스로 구성되어 있습니다. 화학요법을 받는 환자 중 상당수가 헤모글로빈 수치가 10 g/dL 미만인 상태이므로, 이는 환자의 삶의 질에 영향을 미치고 의료비 증가로 이어지기 때문에 효과적인 개입 조치의 필요성이 매우 높다고 할 수 있습니다. 안전성에 대한 우려로 인해 이 시장은 혈액 세포 증식 인자에서 새로운 약물로 전환되고 있으며, 이는 혁신과 다양화를 가져오고 있습니다. 정맥 내 투여를 통한 철분 결핍증 치료는 수혈의 필요성을 줄일 뿐만 아니라 입원 기간을 단축시켜 의료 서비스 제공업체에게 경제적 이점을 가져다줍니다. 각 제약사는 바이오시밀러 에포에틴 및 병용 키트의 도입을 통해 대응을 추진하고 있으며, 이를 통해 치료의 질을 향상시키는 동시에 비용 절감을 도모하고 있습니다.
세계 화학요법 유발 빈혈 시장의 성장 요인
다양한 인구 집단에서 암 유병률이 증가함에 따라 화학요법을 받는 환자 수가 늘어나고 있으며, 이 치료는 종종 빈혈 발병과 관련이 있습니다. 이러한 상황으로 인해, 헤모글로빈 수치를 안전하게 회복시키고 환자의 삶의 질을 향상시키는 것을 목표로 하는 효과적인 치료법에 대한 지속적인 수요가 발생하고 있습니다. 그 결과, 의료 서비스 제공업체와 종양 센터에서는 승인된 빈혈 관리 솔루션을 점점 더 우선적으로 채택하고 있으며, 이는 시장의 지속적인 성장에 기여하고 있습니다. 또한, 환자 지원 단체들은 피로를 줄이고 화학요법 치료 순응도를 높이기 위해 빈혈 관리가 중요하다고 강조하고 있으며, 이로 인해 화학요법 유발 빈혈 시장의 성장 추세가 더욱 가속화되고 있습니다.
세계 화학요법 유발 빈혈 시장의 제약 요인
생물학적 제제인 에리스로포이에틴 제제의 높은 비용은 의료 제도에 있어 큰 과제가 되고 있습니다. 특히, 예산이 제한적이고 의약품 조달에 제약이 있는 저·중소득 지역에서는 그 영향이 두드러집니다. 보험사는 비용 대비 효과를 중시하는 엄격한 보상 방침을 빈번히 도입하고 있으며, 이로 인해 의료 제공업체들은 더 저렴한 대체 치료법을 모색하거나 필요한 시술을 연기할 수밖에 없는 상황에 처해 있습니다. 이러한 재정적 부담은 고가의 치료법이 보급되는 것을 방해할 뿐만 아니라, 제약사가 다양한 의료 현장에서 널리 받아들여지도록 하는 데 어려움을 겪고 있어 시장 전체의 확장을 저해하고 있습니다. 게다가 병원에서는 다른 서비스에 자금을 우선적으로 배분하는 경우가 많아, 그 결과 빈혈 관리 솔루션에 대한 투자가 지연되고, 결국 시장 수요를 감소시킬 가능성이 있습니다.
세계 화학요법 유발 빈혈 시장 동향
세계 항암치료 유발성 빈혈 시장에서는 맞춤형 치료의 통합을 향한 뚜렷한 추세가 나타나고 있으며, 유전적 요인이나 항암치료 요법 등 개별 환자의 특성에 기반한 맞춤형 빈혈 관리가 중시되고 있습니다. 이러한 접근 방식은 치료 효과를 높일 뿐만 아니라 부작용을 최소화하는 데에도 기여하며, 철분 대사 및 적혈구 생성 반응을 평가하는 첨단 진단 도구에 대한 수요 증가를 가져오고 있습니다. 임상의들이 정밀 종양학을 임상 현장에 도입함에 따라, 동반 진단 및 맞춤형 투여 제형 개발에 대한 관심이 높아지고 있습니다. 이러한 변화는 맞춤형 투여 일정 및 바이오마커 기반 치료를 촉진함으로써 시장의 잠재력을 확대하고 있으며, 궁극적으로는 전 세계 환자의 예후를 개선하고 전반적인 치료 효과를 높이는 것을 목표로 하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 화학요법 유발 빈혈 시장 규모 : 치료별
세계의 화학요법 유발 빈혈 시장 규모 : 암 유형별
세계의 화학요법 유발 빈혈 시장 규모 : 유통별
세계의 화학요법 유발 빈혈 시장 규모 : 최종사용자별
세계의 화학요법 유발 빈혈 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.07.08Global Chemotherapy Induced Anemia Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.61 Billion in 2025 to USD 2.52 Billion by 2033, growing at a CAGR of 5.81% during the forecast period (2026-2033).
The global chemotherapy induced anemia market comprises various products and services aimed at preventing, diagnosing, and treating anemia associated with chemotherapy, including erythropoiesis-stimulating agents, iron supplements, and biosimilars. With a significant portion of chemotherapy patients experiencing hemoglobin levels below 10 g/dL, the need for effective interventions is critical, as it impacts patients' quality of life and increases healthcare costs. The market has transitioned from blood-cell growth factors to newer agents due to safety concerns, leading to innovation and diversification. Addressing iron deficiency with intravenous treatments not only reduces transfusion needs but also shortens hospital stays, presenting economic advantages for healthcare providers. Manufacturers are adapting by introducing biosimilar epoetins and combination kits, enhancing care quality and driving down costs.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chemotherapy Induced Anemia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Chemotherapy Induced Anemia Market Segments Analysis
Global chemotherapy induced anemia market is segmented by treatment, cancer type, distribution, end-user and region. Based on treatment, the market is segmented into Erythropoiesis-Stimulating Agents (ESAs), Blood Transfusion, Iron Supplements and HIF-PHI Drugs (Pipeline). Based on cancer type, the market is segmented into Solid Tumors and Hematologic Malignancies. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Oncology Centers and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Chemotherapy Induced Anemia Market
The rising prevalence of cancer among various populations leads to a higher number of patients receiving chemotherapy, a treatment often associated with the development of anemia. This condition necessitates ongoing demand for effective therapies aimed at safely restoring hemoglobin levels and enhancing patient quality of life. As a result, healthcare providers and oncology centers increasingly prioritize approved anemia management solutions, contributing to the continuous growth of the market. Furthermore, advocacy organizations highlight the importance of addressing anemia to alleviate fatigue and promote adherence to chemotherapy treatments, further solidifying the upward trend of the chemotherapy-induced anemia market.
Restraints in the Global Chemotherapy Induced Anemia Market
The high cost of biologic erythropoietin products presents significant challenges for healthcare systems, especially in low- and middle-income areas where limited budgets restrict drug acquisition. Payers frequently implement strict reimbursement policies that emphasize cost-effectiveness, prompting healthcare providers to explore alternative, more affordable treatments or to delay necessary interventions. This financial strain not only hinders the uptake of premium therapies but also stunts overall market expansion, as manufacturers struggle to gain widespread acceptance in various healthcare settings. Additionally, hospitals often prioritize funding for other services, which can result in delayed investments in anemia management solutions and subsequently reduce market demand.
Market Trends of the Global Chemotherapy Induced Anemia Market
The Global Chemotherapy Induced Anemia market is witnessing a significant trend toward personalized therapy integration, emphasizing tailored anemia management based on individual patient characteristics such as genetics and chemotherapy regimens. This approach not only enhances treatment efficacy but also minimizes adverse events, leading to increased demand for advanced diagnostic tools that assess iron metabolism and erythropoietic response. As clinicians adopt precision oncology practices, there is a growing focus on developing companion diagnostics and customizable dosing formulations. This shift is broadening market potential by promoting adaptive dosing schedules and biomarker-guided treatments, ultimately aiming to improve patient outcomes and enhance overall therapeutic effectiveness worldwide.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Chemotherapy Induced Anemia Market Size by Treatment & CAGR (2026-2033)
- Market Overview
- Erythropoiesis-Stimulating Agents (ESAs)
- Blood Transfusion
- Iron Supplements
- HIF-PHI Drugs (Pipeline)
Global Chemotherapy Induced Anemia Market Size by Cancer Type & CAGR (2026-2033)
- Market Overview
- Solid Tumors
- Hematologic Malignancies
Global Chemotherapy Induced Anemia Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
Global Chemotherapy Induced Anemia Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Oncology Centers
- Hospitals
Global Chemotherapy Induced Anemia Market Size & CAGR (2026-2033)
- North America (Treatment, Cancer Type, Distribution, End-User)
- US
- Canada
- Europe (Treatment, Cancer Type, Distribution, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment, Cancer Type, Distribution, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment, Cancer Type, Distribution, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment, Cancer Type, Distribution, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Amgen Inc. (Epogen, Aranesp)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (Procrit/Eprex)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche (NeoRecormon)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vifor Pharma (CSL Behring)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Akebia Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- FibroGen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma (Roxadustat)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca (Roxadustat)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline (Daprodustat)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan (Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- 3SBio Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kyowa Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hetero Drugs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocon Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Reliance Life Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
